603259 WuXi AppTec
- 45.58
- +0.36+0.80%
WuXi AppTec News
Yao Ming Kangde (02359.HK) spent 2005 million yuan to buy back 441,000 A shares on May 16
On May 16, Ge Longhui (02359.HK) issued an announcement to buy back 441,000 A-shares at a cost of RMB 2005 million on May 16, 2024.
Yao Ming Kangde (02359.HK) received an increase of 1,886,000 H shares by Schroder Investment, worth approximately HK$78.948,900
On May 16, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on May 16, Schroders PLC (Schroders PLC) increased its holdings of $1,886 million H shares at an average price of HK$41.8605 per share on May 14, worth about HK$78.9489 million. After the increase in holdings, Schroder Investment's latest shareholding was 19.72.28 million shares, and the good position ratio increased from 4.61% to 5.10%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange, majority shareholders (holding 5% of shares or more
The 40-1 ratio is huge! The new version of the US House of Representatives “Biosafety Act” was passed in a hearing. The industry suggests paying attention to the subsequent run-in between the two house versions of the bill
① At the US House of Representatives hearing, the new version of the “Biosafety Act” was passed with a 40-1 vote; ② Compared with the previous version, the new bill made adjustments in the exemption period for existing contracts/products; at the same time, the companies involved clearly added pharmacological agents; ③ industry experts believe that rapid decoupling is not in the interests of the US industry; next, we need to focus on the run-in between the two houses of law.
The biotechnology sector of Hong Kong stocks weakened, with Zaiding Pharmaceuticals falling more than 6%, Pharmaceutical Kangde falling more than 5%, and Pharmaceutical Biotech and Zhaoyan New Pharmaceutical falling.
The biotechnology sector of Hong Kong stocks weakened, with Zaiding Pharmaceuticals falling more than 6%, Pharmaceutical Kangde falling more than 5%, and Pharmaceutical Biotech and Zhaoyan New Pharmaceutical falling.
Passed! Pharmacovigilance waited for an 8-year buffer period, and the company quickly responded
The new version of the US Biosafety Act (H.R. 8333) (hereinafter referred to as the “Act”) has ushered in the latest developments.
Express News | Yao Ming Kant: The company did not pose a national security risk to the US or any other country in the past, now, and in the future
Express News | US House of Representatives hearing votes to pass the new version of the “Biosafety Act”
Yao Ming Kangde (02359) spent 2.046 million yuan to buy back 442,000 A shares on May 15
Yao Ming Kangde (02359) issued an announcement to spend RMB 2.046,000 to return it on May 15, 2024...
CRO concept stocks fluctuated lower. Hongbo Pharmaceutical fell more than 10%, while Haite Biotech, Pharmaceutical Science, Pharmaceutical Kangde, Haofan Biotech, and Medici followed suit.
CRO concept stocks fluctuated lower. Hongbo Pharmaceutical fell more than 10%, while Haite Biotech, Pharmaceutical Science, Pharmaceutical Kangde, Haofan Biotech, and Medici followed suit.
Express News | CITIC Construction Investment: The national biotechnology and biomanfacture action plan is expected to be introduced in the near future, and the subsequent implementation of the policy is worth looking forward to
Yao Ming Kangde (02359) repurchased 4242,300 A shares on May 14
Yao Ming Kangde (02359) announced that on May 14, 2024, it cost about 2.048,700 yuan to buy back 42...
Express News | Northbound Capital's net sales of 6.67 billion yuan today and the US group had a net sale of 442 million yuan
Xiaomo reduced its holdings of Medicinal Kangde (02359.HK) by about 726,700 shares at a price of about HK$37.48 per share
According to the latest data from the Hong Kong Stock Exchange, on May 7, Xiaomao reduced its holdings of Pharmaceutical Kangde (02359.HK) by 7266.84 million shares, with an average price of HK$37.4841 per share, for a total amount of about HK$27.2391 million. After the holdings were reduced, the latest number of shares held was approximately 307.941 million shares, with a shareholding ratio of 7.95%.
Hong Kong Stock Afternoon Review | Tech Index rose nearly 1%, TechNet stocks and biotech stocks rose higher, Bilibili rose more than 6%, and Laikai Pharmaceuticals rose more than 12%
Auto stocks rose more than 6%; Great Wall Motor rose more than 6%; NIO and Zero Sports Auto rose more than 5%; many coal stocks fell sharply, Yankuang Energy fell more than 6%, and Shougang resources fell nearly 6%.
Express News | Hong Kong Stock Afternoon Review: Hang Seng Technology Index rose 0.98%, Pharmaceuticals, Kangde rose more than 6%
Intraday Overview | Tech Index rose more than 1%, and TechNet stocks were trending strongly. Bilibili rose more than 6%; Tencent Music rose more than 9% after its performance
Technology Network stocks rose collectively, with Bilibili up more than 6%, Kuaishou and Xiaomi Group up more than 3%; auto stocks improved, Great Wall Motor rose more than 7%, NIO rose nearly 6%, and Zero Sports Auto rose nearly 5%.
The Hong Kong stock CXO concept market surged higher at the beginning, and Yao Ming Kangde rose more than 6%
The Hong Kong stock CXO concept market initially surged higher, with Yao Ming Kangde rising more than 6%, Kanglong Chemical and Kingsry Biotech rising by more than 5%, and Pharmaceutical Biotech and Zhaoyan New Pharmaceutical.
Express News | Galaxy Securities: Judging from the pace of the industry's revenue growth rate, the first quarter of 2024 is expected to be the lowest point in the pharmaceutical industry in the whole year
Yao Ming Kangde (02359) spent about 2.046,900 yuan to buy back 432,200 A shares on May 13
According to the Zhitong Finance App, Yao Ming Kangde (02359) issued an announcement to repurchase 432,200 A-share shares with an investment of approximately RMB 2.046,900 (RMB, same below) on May 13, 2024, at a repurchase price of 45.8-48.15 yuan per share.
J.P. Morgan sold 726,700 H shares of Yao Ming Kangde (02359.HK), worth approximately HK$27.391 million
On May 13, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on May 13, JPMorgan Chase & Co. (JPMorgan Chase & Co.) sold $726,700 H-share shares worth about HK$27.4841 on the market and HK$37.4881 per share on the market on May 7. After the sale, J.P. Morgan Chase's latest shareholding was 30.7941 million shares, and the good position ratio dropped from 8.14% to 7.95%. Image source: What is the Stock Exchange's equity disclosure
Analysis
Price Target
No Data
